Drug Trial Radar · NCT07593924
Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
Last checked: Nov 19, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
May 2026
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Sinovac Life Sciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 42 days, up to 89 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.
Conditions
- Pneumococcal Infectious Diseases
Interventions
Sinovac PCV13Biological
One dose of Sinovac PCV13 (0.5ml) was administered at 2, 4, and 12-15 months of age.
Prevenar 13™Biological
One dose of Prevenar 13™ (0.5ml) was administered at 2, 4, and 12-15 months of age.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations≥0.35 μg/mL .Time frame: 30 days after dose 2.
- Geometric mean concentrations (GMCs) of serotype-specific IgG antibody.Time frame: 30 days after dose 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Health Index Multispecialty Clinic (HIMC) Research and Development on Medical Sciences
Imus, Cavite, Philippines
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.